Liver/Biliary Disorders News

Mycophenolic acid, sirolimus and steroids were associated with an increased risk for COVID-19-related hospitalization among those who underwent kidney, liver, heart or lung transplant, data from JAMA Network Open showed.

The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor agonist-antagonist peptide for the treatment of ascites resulting from all causes except cancer, according to a company release.

In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted how rebranding nonalcoholic fatty liver disease as metabolic dysfunction-associated steatotic liver disease offers a “positive diagnosis” without the associated stigma.

The renaming of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease to metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease is a long time coming.

In June 2023, 74% of respondents from a multinational, multisociety Delphi process agreed that the term nonalcoholic fatty liver disease was “sufficiently flawed” and 89% preferred nomenclature that described the underlying cause of disease.

Heavy binge drinking and high polygenic risk score were associated with a sixfold higher relative excess risk for alcohol-related cirrhosis, with the presence of diabetes mellitus further increasing the risk, researchers reported.

Researchers recommended that patients with steatotic liver disease who are at a lower risk for advanced cirrhosis should consume no more than 7.4 grams of alcohol per day, the equivalent of a half a 12 oz. beer or half a glass of wine.

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about interim results from the phase 2a INTEGRIS-PSC trial presented at The Liver Meeting, which showed bexotegrast reduced biomarkers of liver fibrosis vs. placebo.

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about research assessing the role of Claudin-1 in cholangiocarcinoma, which was presented at The Liver Meeting.

Medications that target bile acid-triggered pathways and combination therapies could be the key for treating nonalcoholic steatohepatitis for young people with obesity and type 2 diabetes, according to a speaker.